
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 17, 2026, 12:12 PM ET
Omeros shifts regulatory focus beyond EU after CHMP rejection; OMS527 trial start delayed to 2027
Nasdaq: $OMERYARTEMLEA U.S. launchNTAP effective October 1EU refusal and liquidity
OMER Stock Hub: Omeros Corporation News, YARTEMLEA Sales and EU Refusal
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) confirmed its negative opinion after re-examination, announced by Omeros on October 16, 2026; the U.S. approval remains a separate regulatory outcome. Third-quarter results, reported on November 16, 2026, show YARTEMLEA net revenue of $35.9 million, up 26% from the second quarter, operating income of $4.5 million and positive operating cash flow of $13.3 million. Cash and short-term investments were $95.3 million at September 30, after the July convertible-note repurchases; the GAAP net loss of $57.4 million includes a $62.0 million non-cash derivative loss.
Research Library
Omeros research updated November 17, 2026
37 pages · Q3 YARTEMLEA revenue and cash flow, financial resources, 340B outpatient reimbursement and study plans.
Next company-guided milestones · late 2026 to Q1 2027
ARDS and TA-TMA prevention studies expected to start in late 2026 or early 2027 · Medicare outpatient change on January 1, 2027
Omeros reported third-quarter 2026 results on November 16, 2026, after the market close, and held a conference call and webcast; the replay is available for 90 days. The company expects two open-label, single-arm YARTEMLEA studies, in hyperinflammatory ARDS and in TA-TMA prevention in high-risk pediatric transplant patients, to start in late 2026 or early 2027, subject to ethics approvals; it cites favorable Medicare outpatient reimbursement for 340B-acquired YARTEMLEA from January 1, 2027, and plans OMS527 Phase 2 enrollment in cocaine use disorder in the first quarter of 2027. No exact study start date is announced. Q3 2026 results, November 16, 2026 · October company update.
Dated reimbursement milestone already effective: the Medicare new technology add-on payment (NTAP) began October 1, 2026. The maximum add-on is conditional and is not a guaranteed payment or product price. CMS FY2027 rule.
OMER stock: dated key data
Chart analysis · JC
Technical chart analysis of $OMER with bull and bear scenarios on JC Just Charts.
Cash + investments · September 30
$95.3M
Cash and short-term investments at September 30, 2026, after the July note repurchases.
Q3 YARTEMLEA net revenue
$35.9M
Quarter ended September 30, 2026; gross revenue $41.8M, gross-to-net adjustment 14.0%.
Q3 operating income
$4.5M
September quarter; distinct from the $57.4M GAAP net loss.
Q3 operating cash flow
+$13.3M
Company-wide quarter figure; not recurring guidance.
Common shares
74.464M
74,463,571 at November 11, 2026 cover date.
Notes principal after July
$40.322M
2029 convertible notes after July repurchases; not June carrying value.
Total shareholders’ deficit
−$89.973M
September 30, 2026; widened by the non-cash derivative remeasurement.
Financial figures: September Form 10-Q · Q3 release. The September balance already reflects the July note repurchases.
OMER today: U.S. launch quality and the post-July balance sheet
The U.S. label covers TA-TMA in adults and pediatric patients aged two years and older. Europe has not granted marketing authorization: the CHMP maintained its refusal recommendation. Omeros says it intends to end compassionate use while completing existing patients’ courses and pursuing reimbursed named-patient access where permitted; this is not an EU approval. U.S. label · EMA record · Company statement.
Net revenue rose from $9.893M in Q1 to $28.529M in Q2 and $35.9M in Q3. Q3 operating income was $4.5M and operating cash flow was positive for a second consecutive quarter, at $13.3M. The gross-to-net adjustment rose to 14.0% from 11.5% as purchases by entities covered by the 340B drug-pricing program increased, which the company links to wider outpatient use. The GAAP net loss of $57.4M includes a $62.0M non-cash loss, mainly on the derivative tied to the 2029 notes; non-GAAP adjusted net income was $4.7M. July repurchases reduced conversion exposure but consumed substantially more cash than the principal retired. Gregory A. Demopulos, chairman and CEO, said revenue continued to grow in the fourth quarter; that is a company statement, not a reported figure. Q3 results · Financial details.
Main risk: Commercial sales must remain durable after the launch quarter. Cash and short-term investments fell to $95.3M at September 30 after the July note repurchases, EU authorization is absent, and reimbursement eligibility does not create prescriptions or guarantee collection.
Constructive case
Repeat U.S. demand and effective reimbursement could sustain operating progress. Reduced convertible principal lowers potential note-related dilution if funded without compromising commercial execution.
Cautious case
Weak repeat demand, safety or access issues could tighten liquidity after the repurchases. Europe remains unavailable for routine authorized sales, and future financing can reintroduce dilution.
OMER stock news: six selected updates
Nov 17, 2026
Omeros shifts regulatory focus beyond EU after CHMP rejection; OMS527 trial start delayed to 2027
The EMA's CHMP issued a negative opinion in October on the marketing authorization application for narsoplimab (Yartemlea in the U.S.), after re-examining its June decision. CEO Greg Demopulos said the company is shifting near-term regulatory strategy outside the EU and intends to close the EU compassionate-use program to new patients. Enrollment in the OMS527 cocaine use disorder trial is now expected in early 2027, with data still expected in 2027. Q3 Yartemlea gross sales were $41.8 million and net sales $35.9 million. Reported by the press from an official company announcement; the primary document was not yet available in our sources at the time of writing.
Nov 16, 2026
Omeros Corporation Reports Third Quarter 2026 Financial Results
Omeros reported YARTEMLEA gross revenue of $41.8 million for the third quarter of 2026, up 30% from $32.2 million in the second quarter. Net revenue rose 26% to $35.9 million, while GAAP net loss was $57.4 million, or $0.79 per share, including a non-cash loss of $62.0 million. Cash and short-term investments totaled $95.3 million at September 30, 2026, and operating cash flow was $13.3 million in the quarter.
Nov 10, 2026
Omeros Corporation to announce third quarter financial results on November 16, 2026
Omeros Corporation (NASDAQ: OMER) will issue its financial results for the third quarter of 2026 on Monday, November 16, 2026, after market close. Management will host a conference call and webcast the same day to discuss recent developments and financial results. A replay will be available for 90 days in the Archived Events section of the Investor Relations page.
Oct 30, 2026
CEO receives a performance-based option tied to stock-price hurdles
On October 28 the compensation committee granted the CEO an option on up to 500,000 shares at a $17.88 exercise price, the grant-date close. Four equal tranches vest only if the 30-day volume-weighted price reaches $25, $30, $35 and $40 during the five-year term, plus a time-based service schedule. Nothing vested and no shares were issued at grant; the award expires October 28, 2031.
Oct 16, 2026
CHMP refusal recommendation confirmed after re-examination
The EMA product record confirms the refusal recommendation and says the concerns about evidence of effectiveness remained unresolved after re-examination. Omeros separately criticizes the process and describes intended compassionate-use changes and named-patient efforts; those descriptions are the company's account, not independent regulatory findings.
Aug 13, 2026
Incentive-plan S-8 registers additional capacity
The filing registers 10,406,236 additional common shares under the incentive plan. Registration is capacity rather than immediate issuance of the entire amount.
OMER stock catalysts: dated milestones
- November 16, 2026 · Q3 2026 results reported after the close · call held the same dayCompleted
YARTEMLEA net revenue of $35.9M, operating income of $4.5M, operating cash flow of $13.3M and $95.3M of cash and short-term investments at September 30. Company release.
- October 1, 2026 · FY2027 NTAP effectiveEffective milestone · uptake remains a commercial test
Payment depends on eligible cases and the statutory calculation. CMS source.
- Late 2026 or early 2027 · ARDS and pediatric TA-TMA prevention studiesCompany plan on November 16 · subject to ethics approvals
Open-label, single-arm studies with historical controls, about 50 to 60 patients each; these are additional research indications, not newly approved uses. Q3 release.
- January 1, 2027 · Medicare outpatient reimbursement for 340B-acquired YARTEMLEACompany-cited reimbursement change
A payment rule, not a sales figure. Q3 release.
- Q1 2027 · OMS527 Phase 2 enrollment in cocaine use disorderCompany target · NIDA-funded
Enrollment follows a nonclinical study requested by the FDA. Q3 release.
- June 2029 · Remaining convertible-note maturityContractual maturity · subject to note terms
July repurchases leave approximately $40.322M principal; the maturity is a financing date, not a product catalyst. Debt note.
OMER YARTEMLEA access: U.S. reimbursement and European refusal
The permanent J-code J1289 took effect July 1 and NTAP on October 1. NTAP is limited to the lesser of 65% of the technology’s average cost or 65% of case costs above the MS-DRG payment, with a maximum $287,079. Reimbursement support and hospital demand are different steps.
The European recommendation remains negative after re-examination. Named-patient access, where permitted, would not replace routine marketing authorization. The pivotal evidence described in the U.S. label is single-arm, without a randomized concurrent control; external comparisons do not remove that limitation. The U.S. label also carries serious infection warnings. CMS · EMA · U.S. label.
OMER cash, convertible notes and dilution
At September 30, 2026, 2029-note principal was $40.322M, the net carrying amount $31.891M and the separate embedded derivative $101.136M. The OMIDRIA royalty obligation was $152.962M, non-recourse except to the designated royalty rights; it is distinct from the convertible notes and YARTEMLEA product sales. September Form 10-Q, filed November 16.
Chapter 08 covers reported cash and cash flow, chapter 09 provides the debt and July repurchase bridge, and chapter 10 separates issued shares from options and potential future dilution. Conditional partner milestones and unused facilities are different from money received.
Omeros Corporation deep dive: the full analysis
The U.S. YARTEMLEA franchise, clinical evidence, reimbursement, the European refusal and the financial structure behind the commercial transition. The Merlintrader Research Library collects our dated biotech stock research reports.
01 Bull, base and bear scenarios for the commercial transition
Merlintrader reading — conditional scenarios, not forecasts. Omeros now has reported commercial revenue and operating cash generation, alongside a U.S.-centered product franchise and a complex capital structure. The relevant outcomes depend on durability, access and the cost of funding retained research.
Bull scenario
Repeat U.S. demand continues after the initial launch period. Hospitals use YARTEMLEA earlier in treatment protocols, reimbursement infrastructure reduces friction and growing gross profit supports both commercial spending and a disciplined pipeline. The November 16 results provide a stronger starting point: third-quarter net revenue of $35.9 million and positive company-wide operating cash flow. They do not determine the performance of subsequent quarters. Company results · November 16, 2026
The constructive path also requires resources to remain adequate after the July note repurchases. Retiring convertible principal reduces potential conversion exposure, while cash must still cover commercial operations, interest and development. Novo Nordisk milestone payments would add another source of funding if the relevant events occur; they are conditional and cannot be assumed simply because a transaction headline contains a large total potential value. SEC · Q3 Form 10-Q, November 16, 2026
Base scenario
U.S. sales grow unevenly from center to center. The product has a dedicated label and improving access arrangements, but treatment incidence, clinical judgment, dosing and payer mix make individual quarters variable. Europe remains outside routine authorized commercialization after the negative re-examination outcome. Named-patient access, if achieved, remains distinct from a marketing authorization. Company European update · October 16, 2026
Merlintrader reading. This scenario combines a viable commercial franchise with continued uncertainty over normalized margins and cash conversion. The reimbursement changes are useful infrastructure; subsequent orders and collections show whether that infrastructure is translating into durable use. The accounting derivative can make reported net income volatile even while the operating business improves. Assessing the company solely from a GAAP earnings headline would obscure those separate mechanisms. SEC · Q3 Form 10-Q, November 16, 2026
Bear scenario
Repeat demand slows, treatment remains concentrated in late rescue use, serious safety or access issues emerge, or expenses expand faster than gross profit. The post-repurchase liquidity position would then provide less flexibility. Pediatric competition, a harder reimbursement mix or costly new studies could add pressure before a broader franchise develops. Company results · November 16, 2026
Merlintrader reading. Clinical or commercial progress need not produce the same outcome per existing share. Future debt, equity issuance or asset monetization can change the economics. Under the adverse scenario, Omeros must address those financing choices while protecting launch execution. None of these paths is a price target; the evidence that distinguishes them is reported demand, net revenue, cash flow, safety and capital terms. SEC · Q3 Form 10-Q, November 16, 2026
What would falsify this reading
Merlintrader reading. The central interpretation is a commercial transition with improving U.S. economics, a closed routine EU route and a need to distinguish operating performance from financial accounting. Four observations would materially change it. SEC · Q3 Form 10-Q, November 16, 2026
- Demand quality weakens. Reordering and collections fail to sustain the revenue growth reported in the September quarter. That would weaken the interpretation even with a permanent billing code and NTAP in place.
- Access changes the commercial market. A new European authorization or material reimbursed named-patient use would change the present U.S. concentration. A proposed access route alone would not.
- Competitive evidence changes treatment choices. A rival gains a relevant label, stronger comparative evidence or materially easier implementation. Existing off-label protocols also remain a practical competitor.
- The financing bridge changes. Durable operating cash generation or completed non-dilutive milestones reduce pressure; weak cash conversion or a new raise on burdensome terms increase it. Conditional capacity is different from money received.
The November 16 quarterly results, the EMA assessment and future regulatory or financing announcements provide distinct evidence for these questions. A single favorable measure should not be used as a substitute for all of them. EMA · Yartemlea assessment
The current operating baseline is the quarter ended September 30, reported November 16. Later sales comments from management are directional statements until a subsequent period is reported. Company results · November 16, 2026
02 What Omeros sells and why the treatment setting matters
Omeros is a commercial-stage biotechnology company centered on complement biology. Its U.S. product YARTEMLEA is narsoplimab-wuug, a monoclonal antibody targeting MASP-2 in the lectin pathway of complement. The FDA indication covers hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and pediatric patients aged two years and older. U.S. distribution began in January 2026 (SEC · Q3 Form 10-Q, November 16, 2026). FDA · December 2025 prescribing information
TA-TMA can involve endothelial injury, small-vessel thrombosis, blood-cell destruction and organ dysfunction following transplantation. These patients may also face infection, graft-versus-host disease, immunosuppression and other overlapping complications. The clinical context makes diagnosis, treatment timing and attribution of outcomes difficult. A dedicated product label addresses a severe unmet need but does not make every transplant recipient eligible for treatment. FDA · December 2025 prescribing information
MASP-2 inhibition targets the lectin complement pathway. Downstream C5 inhibition is a different mechanism and has been used off label in this setting. A mechanistic distinction is relevant to medical decisions, but patient outcomes and safety determine whether it produces useful clinical differentiation. The U.S. label warns about serious and life-threatening infections; the absence of a boxed warning is not the absence of a serious safety risk. FDA · December 2025 prescribing information
Administration and dosing depend on the approved label and patient characteristics. Weight-based dosing applies below 50 kilograms, with fixed dosing at or above that threshold, generally weekly and potentially twice weekly when improvement is inadequate. Practical implementation involves specialist centers, clinical assessment, infusion capacity, hospital processes and payer rules, rather than a simple community prescription model. FDA · December 2025 prescribing information
Merlintrader reading. The concentrated transplant-center market can make education and account coverage efficient, but it also makes a relatively small set of institutional decisions important. Repeat use, earlier recognition and integration into center protocols would be more informative than the number of sales contacts or the theoretical number of transplants. The product has to earn a place within a complicated care pathway. SEC · Q3 Form 10-Q, November 16, 2026
Omeros previously commercialized OMIDRIA before selling the product and monetizing retained U.S. royalties. The current royalty obligation is described in chapter 09. The company also transferred global zaltenibart development and commercialization rights to Novo Nordisk; the retained pipeline and conditional partner economics are discussed in chapter 12. Those assets have different sources of revenue, control and risk. SEC · Q3 Form 10-Q, November 16, 2026
03 Catalysts: commercial execution and the next studies
On November 16, 2026, Omeros outlined two additional YARTEMLEA studies expected to start in late 2026 or early 2027, subject to ethics approvals: one in hyperinflammatory acute respiratory distress syndrome and one in prevention of TA-TMA among high-risk pediatric transplant recipients. The planned open-label, single-arm studies would use historical controls and approximately 50–60 patients each. They are development plans, not new approved indications. Company results · November 16, 2026
The company also identified January 1, 2027 as the effective date of a favorable Medicare outpatient reimbursement change for 340B-acquired YARTEMLEA. That is an access-policy milestone, not an order forecast. The inpatient NTAP and permanent J-code are already effective; their status and limits are explained in chapter 06. Company results · November 16, 2026
OMS527 Phase 2 enrollment in cocaine use disorder is targeted for the first quarter of 2027 after a nonclinical study requested by the FDA. NIDA funding is relevant to the economics of that work. Study start, enrollment completion, results and any eventual approval remain separate events. The November update provides no exact day for the planned clinical starts. Company results · November 16, 2026
Merlintrader reading. The most direct commercial catalyst is a sequence of reported quarters showing recurring demand and cash collection. Management stated that revenue continued to grow in the fourth quarter, but it did not report a fourth-quarter revenue total. An encouraging directional statement is useful context and must remain distinct from a closed financial period. Company results · November 16, 2026
Merlintrader reading. The next development announcements should identify actual initiation, population, design, endpoints and funding. An open-label study with a historical control can provide evidence, but it does not acquire the protections of randomization simply because the population is serious or rare. Each expansion also competes for resources with the existing launch. SEC · Q3 Form 10-Q, November 16, 2026
04 Clinical evidence: the label and its limitations
FDA approved YARTEMLEA on December 23, 2025 (SEC · Q3 Form 10-Q, November 16, 2026). Approval resolves the U.S. marketing decision for the labeled population; it does not turn the underlying single-arm evidence into a randomized trial. FDA · December 2025 prescribing information
The FDA prescribing information reports TMA response in 17 of 28 adults in the pivotal study (60.7%, rounded to 61%) and in 13 of 19 evaluable expanded-access patients (68.4%). The label reports 100-day survival from TMA diagnosis of 73.4% (95% CI 52.2–86.4) in the pivotal study and 73.7% (95% CI 47.9–88.1) in the 19-patient expanded-access cohort. The 2022 Journal of Clinical Oncology publication discussed below reports 68% 100-day survival in its 28-patient full analysis set: that is a survival estimate, not the expanded-access response rate. These are different documents and analyses, not separate pivotal trials (FDA label). The pivotal study was single-arm. FDA granted U.S. approval, while the CHMP maintained its negative opinion after re-examination on October 15, 2026.
The registrational dataset is small, and it is public. The pivotal study, NCT02222545, was single-arm and open-label, and its results appeared in the Journal of Clinical Oncology in 2022: in a full analysis set of 28 adults the response rate was 61%, organ function improved in 20 of the 27 patients with evaluable organ-function data (74%), 100-day survival from TA-TMA diagnosis was 68% across the full analysis set and 94% among responders, and median overall survival was 274 days. Merlintrader reading. Twenty-eight patients is a thin base for an approval, and the missing control arm is the structural limit worth keeping in mind: without a randomized comparator a study cannot separate the effect of the drug from the natural course of a condition whose outcomes vary widely from patient to patient. Khaled et al., J Clin Oncol 2022.
Merlintrader reading. The work published since was built to address that gap, and it should be read for what it is: externally controlled and real-world evidence, not a second randomized trial. A comparative analysis in Blood Advances set narsoplimab-treated patients aged sixteen and over against a matched control group with high-risk TA-TMA drawn from the Kyoto Stem Cell Transplantation Group registry. The hazard ratio for mortality was 0.25, with a 95% confidence interval of 0.19 to 0.34, for the 28 patients of the single-arm study against 111 registry patients; 0.38, interval 0.28 to 0.51, for the 49 high-risk patients treated in the expanded-access program against 121 registry patients; and 0.28, interval 0.22 to 0.37, for the two narsoplimab cohorts combined, 77 patients in all. Each comparison carried a p value below 0.0001. An external control is a stronger argument than no comparator at all and a weaker one than randomization, because matching can only adjust for the variables a registry happens to record. Matsui et al., Blood Advances 2026.
The expanded-access program itself was reported in the American Journal of Hematology and covers 136 patients treated between October 2017 and October 2023. Among children who received an allogeneic transplant and had high-risk TA-TMA, one-year overall survival was 75.0% when narsoplimab was given as first-line therapy, in 12 patients, and 56.2% from second line onwards, in 25 patients, 20 of whom were refractory to eculizumab. Among adults in the same situation it was 58.0% in first line, in 49 patients, and 40.5% from second line, in 16 patients. Merlintrader calculation. Those four high-risk allogeneic subgroups comprise 102 patients within the 136-patient program; they are not the full cohort. The authors reported no concerning safety signals. A separate Italian series in Bone Marrow Transplantation described 20 compassionate-use patients, 13 adults and 7 children, 19 of them high risk: 13 responded, 65% of the group, 100-day survival was 70% overall and 100% among responders, and there was no increase in infectious complications. Merlintrader reading. The denominators matter as much as the percentages here. A figure of 75.0% describes twelve children, and none of these cohorts was treated inside a controlled protocol. Schoettler et al., Am J Hematol 2025; Castelli et al., Bone Marrow Transplant 2024.
Merlintrader reading. The clinical comparisons have to retain their own populations, endpoints and time origins. Response percentages, survival estimates and mortality hazard ratios cannot be exchanged as though they were the same measurement. Externally controlled analyses can add context while retaining residual confounding and selection limits. The label, the published studies and the European assessment therefore need to be read in their own terms. FDA · December 2025 prescribing information
05 YARTEMLEA sales, margins and operating performance
For the quarter ended September 30, 2026, Omeros reported YARTEMLEA gross revenue of $41.8 million and net revenue of $35.9 million. The company described net revenue growth of 26% from the preceding quarter. Gross-to-net adjustments were 14.0%, reflecting increased purchases by 340B-covered entities and a wider outpatient mix. The growth rate and the deduction rate answer different questions. Company results · November 16, 2026
Quarterly operating income was $4.5 million. GAAP net loss was $57.4 million, including a $62.0 million noncash derivative loss mainly related to the 2029 convertible notes. Non-GAAP adjusted net income was $4.7 million. The derivative remeasurement is an accounting change in a financial liability, not a cash payment equal to the loss and not a reversal of product sales. Company results · November 16, 2026
Merlintrader reading. The operating improvement is meaningful because it follows a commercial launch rather than a one-time licensing event. Its durability depends on repeat treatment, realized net revenue and the expense base. A large increase from an early launch quarter does not supply a long-term growth rate. Hospital ordering, treatment duration and channel timing can all affect an individual period. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. Gross-to-net deductions deserve attention alongside gross demand. A larger 340B share can support broader access while changing the amount retained from gross sales. An increase in deductions is therefore not automatically evidence of weaker patient use, and stronger gross sales are not automatically proportionate growth in cash available to Omeros. Product mix, collections and access conditions need to be assessed together. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. The most useful commercial evidence would connect new and returning centers, prescribing patterns, product movement and cash collected. A shipment is not necessarily the same date as treatment, and treatment in a rare condition need not repeat evenly each quarter. Neither a simple annualization of one quarter nor a list-price multiplication can capture those differences. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. The spending side remains important. Omeros is maintaining a commercial organization while proposing new studies and retaining earlier research programs. Operating income shows improvement before financing and nonoperating items, but the cash-flow statement and liabilities help judge whether that improvement is becoming durable financial flexibility. Chapter 08 explains the current liquidity baseline. SEC · Q3 Form 10-Q, November 16, 2026
06 U.S. reimbursement and the separate European outcome
Permanent HCPCS J-code J1289 became effective July 1, 2026. Product-specific coding gives hospitals and payers a consistent way to identify YARTEMLEA in claims. It can reduce administrative ambiguity; it does not require a physician to prescribe or guarantee payment for every claim. Omeros · permanent reimbursement J-code announcement
The FY2027 inpatient NTAP became effective October 1, 2026. The maximum is $287,079 per eligible Medicare inpatient case. The payment is limited to the lesser of 65% of the average technology cost or 65% of case costs above the MS-DRG payment, under the applicable rules. It is an additional payment to the eligible hospital, not a product selling price or a guaranteed amount for every administration. CMS · FY2027 IPPS final rule
CMS used an applicant-estimated 12 vials per inpatient stay and a wholesale acquisition cost of $36,805 per vial to establish the maximum (Federal Register · FY2027 final rule, August 4, 2026). Those inputs describe the payment model, not observed average duration or net revenue per patient. The company says the outpatient reimbursement change for 340B-acquired YARTEMLEA begins January 1, 2027; it should be assessed within its separate outpatient setting. Company results · November 16, 2026
In Europe, the CHMP maintained its negative opinion after re-examination, as announced by Omeros on October 16, 2026. Yartemlea has no EU marketing authorization. EMA identified insufficient evidence of effectiveness, limitations in uncontrolled and external-comparator evidence, and unresolved issues including pediatric evidence and dose selection. The U.S. label and the European outcome are separate regulatory judgments. EMA · Yartemlea assessment
Omeros disagreed with the outcome and described concerns about the expert-review process. That account is the company’s position. It said it intended to end the EU compassionate-use program while allowing current patients to complete their courses, and to pursue reimbursed named-patient access where permitted. Such access would not be routine authorized commercialization, and the statement provides no new approval date. Omeros · October 16, 2026 European update
Merlintrader reading. For the commercial case, U.S. reimbursement support is a reduction in friction, while Europe remains a separate barrier to broad market access. Better hospital economics can help a clinical decision become a feasible treatment, but they cannot create clinical demand. A named-patient effort could have value without representing the same market as an authorization. Revenue assumptions should preserve those distinctions. Company results · November 16, 2026
07 Competition and the limits of market-size arithmetic
AstraZeneca announced July 27, 2026 that its randomized adult/adolescent Ultomiris HSCT-TMA trial did not achieve statistical significance on the primary endpoint of event-free survival through 26 weeks. The study enrolled 146 patients. The company described a trend toward benefit and continuing discussion with authorities; the missed endpoint does not demonstrate that every C5 approach is ineffective. AstraZeneca · regulatory announcement, July 27, 2026
The same announcement described a separate open-label pediatric study enrolling 41 patients, with reported overall survival of 87.2% at 26 weeks and 73.4% at 52 weeks, and plans to advance pediatric regulatory filings supported by those data and an external control. The treated-group survival figures are not an effect measured against a randomized concurrent comparator. AstraZeneca · regulatory announcement, July 27, 2026
Merlintrader reading. The adult endpoint miss supports Omeros’ current position but does not create a permanent monopoly. Off-label practice, competing center protocols and future pediatric regulatory decisions can affect use. Mechanism, safety, administration, evidence and reimbursement all enter the treatment decision. A competitor’s difficulty is not proof of the magnitude of YARTEMLEA’s own benefit. FDA · December 2025 prescribing information
Merlintrader reading. The addressable market cannot be estimated reliably by multiplying total transplants by the highest published incidence and a list price. Diagnostic definitions vary; some patients will not be treated, timing and duration differ, and reimbursement depends on setting and payer. The theoretical burden of disease is therefore different from the number of treated patients in a reported sales period. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. Earlier protocol adoption and late rescue use would produce different commercial patterns. Earlier recognition could broaden the treated pool and change duration; rescue-only use could concentrate treatment in a smaller and more severely ill group. A single sales figure cannot reveal the mix. Center-level repeat use and clinical implementation would be more useful than an unsupported point estimate of total market sales. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. The CMS vial and cost assumptions explain a reimbursement formula; they should not be substituted for realized net revenue per patient. Gross-to-net deductions, free supply, payer mix, treatment setting and collections all intervene. This is why the reported net revenue and cash-flow progression remain central even when the potential disease burden appears large. CMS · FY2027 IPPS final rule
08 Cash, operating cash flow and the post-repurchase baseline
Cash and short-term investments were $95.3 million at September 30, 2026. This reported balance is after the July convertible-note repurchases. The balance reflects the July note repurchases as well as receipts, spending and investment movements through quarter-end. Company results · November 16, 2026
Company-wide operating cash flow was positive $13.3 million in the third quarter, the second consecutive positive quarter. That is an actual reported quarter, not guidance for every subsequent quarter. Working-capital movements, cash collections and operating payments affect the relationship between income and cash flow. Company results · November 16, 2026
In the September-quarter filing, management expects current resources and anticipated YARTEMLEA sales receipts to fund operations for more than twelve months from issuance. The statement depends on expected commercial receipts and spending. It is not an unconditional cash guarantee or a fixed date at which the company must next raise capital. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. The combination of a reported post-repurchase balance and positive quarterly cash flow improves the visibility of the funding position. It still leaves questions about normalized product cost, the scale of research spending, commercial collections and interest. A launch that pays for itself for one or two quarters is stronger evidence than an untested forecast, but a longer sequence is needed before treating the cash profile as stable. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. The balance also should not be inflated by adding unused at-the-market (ATM) offering capacity or the entire potential Novo milestone package. Those are possible sources of future money with different conditions. A new financing or a milestone receipt belongs in the cash bridge when it occurs; until then, the September resources and actual operating cash flow provide the factual starting point. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. Liquidity is the capacity to meet obligations and fund a strategy. Shareholders’ deficit, derivative fair value and the royalty accounting obligation influence the financial statements, but none can be substituted directly for a bank balance or summed without regard to settlement terms. Chapter 09 separates those obligations so that the operating funding question remains interpretable. SEC · Q3 Form 10-Q, November 16, 2026
09 Convertible debt, the derivative and OMIDRIA royalties
At September 30, 2026, remaining 2029 convertible-note principal was $40.322 million. The balance-sheet carrying amount was $31.891 million after an $8.431 million unamortized discount. The embedded derivative was a separate $101.136 million liability. The carrying amount, principal and derivative are different accounting measures, not three separate loans to be added at face value. SEC · Q3 Form 10-Q, November 16, 2026
In July, Omeros retired $30.463 million of note principal through negotiated repurchases. Aggregate purchase price was approximately $60.170 million, plus $223,000 of accrued interest. The transaction reduced potential conversion rights by approximately 4.929 million shares, leaving approximately 6.525 million. The transaction cash cost is reflected in the reported September resources discussed in chapter 08. SEC · Q3 Form 10-Q, November 16, 2026
The remaining notes bear 9.50% interest and mature in June 2029, subject to their governing terms. Their conversion rate is approximately 161.81 shares per $1,000 of principal. Redemption and interest make-whole provisions affect settlement. Principal retirement lowers contractual obligations and conversion exposure; it does not imply that the cash purchase price equaled the principal retired. SEC · Q3 Form 10-Q, November 16, 2026
The latest quarterly filing reports a $152.962 million OMIDRIA royalty obligation, comprising $22.338 million current and $130.624 million long-term. This is non-recourse to Omeros and is settled through the designated royalty arrangement. It is different from the convertible notes’ cash obligations and from an unrestricted bank loan. The royalty-sale accounting should be assessed using the contractual cash flows and escrow mechanics. SEC · Q3 Form 10-Q, November 16, 2026
The $62.0 million third-quarter noncash derivative loss affects GAAP income but is not a cash operating outflow of the same amount. Changes in the derivative valuation can create large movements in reported net income even when product revenue and operating income move in the opposite direction. The separate September balances help explain that difference. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. Capital allocation involves a trade-off. Retiring notes reduces future interest and potential conversion dilution, while a purchase price above retired principal uses financial flexibility. Its quality depends on the commercial cash generated afterward and the resources needed for retained development. The July transaction cannot be judged from principal reduction alone, nor from the subsequent derivative loss alone. SEC · Q3 Form 10-Q, November 16, 2026
10 Common shares, options, awards and future dilution
Common shares outstanding were 74,463,571 on November 11, 2026, according to the cover of the September Form 10-Q. This issued-share count differs from weighted-average EPS shares and from shares potentially issuable under options or convertible notes. The remaining conversion exposure is described in chapter 09 and should not be counted as already-issued stock. SEC · Q3 Form 10-Q, November 16, 2026
Omeros retained $150 million of ATM capacity after reporting no ATM sales during the first nine months of 2026. Capacity provides a potential financing route, subject to applicable terms and requirements. It is neither a commitment to issue the full amount nor cash already available on the balance sheet. Using it would increase the common-share count. SEC · Q3 Form 10-Q, November 16, 2026
The August 13, 2026 Form S-8 registered 10,406,236 additional shares under the amended incentive plan. Registration establishes a securities framework for plan awards; it is not evidence that every registered share has been granted, vested or issued. Option exercises, forfeitures and new grants change the eventual share outcome. SEC · Form S-8, August 13, 2026
On October 28, 2026, the compensation committee granted the chief executive a performance-based option for 500,000 shares, disclosed in the October 30 Form 8-K. Vesting depends on specified service and performance conditions. The grant is an option award, not an open-market purchase or the immediate issuance of 500,000 common shares. SEC · October 30, 2026 Form 8-K October 30 Form 4 · code A; no shares vested at grant.
Merlintrader reading. The relevant dilution bridge distinguishes securities that already changed issued shares from contingent rights. A plan registration, an unvested award and a conversion right carry different conditions. A favorable operating quarter does not erase those rights, while their existence does not prove all will become common stock on the same date. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. It is also necessary to distinguish a transaction code from a narrative about insider confidence. A is an award, M an exercise, F tax withholding, S a sale and P a reported purchase. Exercise-related shares followed by a sale are not the same economic action as a fresh open-market purchase. Chapter 11 discusses ownership snapshots and the dated transaction evidence. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. The capital structure remains part of the operating story because cash can be retained, spent on development, used to retire securities or replaced through a new raise. The outcome per share depends on that sequence, rather than the headline scale of a facility or incentive authorization. Reported issued shares and instrument terms provide the baseline for assessing later changes. SEC · Q3 Form 10-Q, November 16, 2026
11 Ownership, insider transactions and short interest
BlackRock reported 5,961,792 shares, or 8.2%, at a June 30, 2026 event date in a Schedule 13G/A filed July 29. These are the filing’s dated shares and percentage. They are not a live holding count and should not be silently rebased to the November common-share denominator. SEC · BlackRock Schedule 13G/A, July 29, 2026
Merlintrader reading. Other historical ownership disclosures use different dates. A residual retail share cannot be obtained reliably by subtracting a handful of dated institutional percentages from 100%, because reports can overlap and omit smaller positions. Named filings are dated snapshots rather than a complete current census. SEC · Omeros Schedule 13G filings
The October chief-executive option award is described in chapter 10. Its performance and service conditions differ from a purchase of outstanding shares. Earlier exercise-and-sale transactions likewise should retain their reported codes and cannot be characterized as market purchases. The evidence of compensation, ownership and personal trading answers different questions. SEC · October 30, 2026 compensation disclosure
FINRA reports 12,833,757 shares short at the October 30, 2026 settlement, with average daily volume of 1,336,486 shares and 9.60 days to cover. This is a settlement snapshot, not a current intraday count. The ratio relates short shares to the reported volume basis; it does not require short sellers to close within 9.60 days. FINRA · October 30, 2026 equity short interest
Merlintrader reading. A large short position can increase sensitivity to changes in expectations and liquidity, but it does not demonstrate an inevitable squeeze. Borrow availability, hedging, trading depth and new share supply can all influence positioning. The report should be used with its date and volume basis rather than converted into a prediction. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. Governance is a further operating consideration. A founder-led company that navigated a long regulatory process must now execute manufacturing, safety monitoring, reimbursement and expense control. The note repurchases and compensation choices can be assessed against sustained commercial cash generation. A successful regulatory defense and a durable commercial organization are related accomplishments, but neither is evidence that every future allocation decision will be effective. SEC · Q3 Form 10-Q, November 16, 2026
12 Novo Nordisk economics and the retained pipeline
The zaltenibart asset-purchase and license transaction closed November 25, 2025, with $240 million paid upfront by Novo Nordisk. Novo received exclusive global development and commercialization rights to the MASP-3 inhibitor, formerly OMS906. The transaction transferred the associated development burden and gave Omeros cash before the U.S. YARTEMLEA launch. Omeros · transaction closing announcement, December 1, 2025
The agreement provides for up to $510 million of development and regulatory milestones, including up to $100 million of near-term milestones, plus up to $1.3 billion of sales milestones. The $100 million is included in the $510 million and must not be added again. Tiered royalties range from the high single digits to the high teens. These are contingent economics, not additional revenue already recognized or cash already collected. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. The partner controls development pace and priorities for the transferred asset. Milestones require specified events, and royalties require sales under the agreement. A large potential transaction total is therefore an opportunity with conditions. It should not be inserted into a cash-runway calculation as though payment had occurred. SEC · Q3 Form 10-Q, November 16, 2026
Omeros retained other programs, including OMS1029, OMS527, oncology and antimicrobial research and certain MASP-3 assets outside the transaction. The November 16 update targets OMS527 Phase 2 enrollment in the first quarter of 2027 following FDA-requested nonclinical work. Its NIDA support is a source of program funding, distinct from product sales and partner milestones. Company results · November 16, 2026
The initial Phase 2 indication for OMS1029 is still being finalized. For OncotoX-AML, also identified as OMS805, IND-enabling work continues and the company targets an initial Phase 1b study in late 2027. These are development plans: preclinical activity is not patient efficacy data, and a projected start is not a trial already initiated. Company pipeline update · November 16, 2026.
The planned ARDS and pediatric TA-TMA prevention studies would extend investigation of YARTEMLEA beyond its present treatment label. The company describes single-arm designs with historical controls and expected starts in late 2026 or early 2027, subject to approvals. Planned research does not authorize those uses in advance, and an announced target is different from a confirmed first-patient event. Company results · November 16, 2026
Merlintrader reading. The pipeline creates a capital-allocation test. The strongest operating pattern would fund the existing franchise properly, advance retained programs through evidence-based decisions and use grants or partnerships where useful. Broad expansion of early research before recurring sales are secure would create a different funding profile. The number of programs is not by itself a measure of their probability of approval or economic value. SEC · Q3 Form 10-Q, November 16, 2026
13 Red flags and the overall assessment
Merlintrader reading. The constructive evidence is stronger than at the beginning of the launch: a U.S. product with a dedicated label, growing reported net revenue, operating income and a second positive operating-cash-flow quarter. Those achievements provide an operating foundation. They should be assessed alongside the remaining uncertainties rather than replaced by a single financing or accounting headline. Company results · November 16, 2026
The first red flag is demand durability. A rare-disease launch can be uneven, and a larger 340B mix changes deductions from gross sales. The second is regulatory concentration: routine EU commercialization remains unavailable following the negative opinion after re-examination. The third is evidence interpretation: a U.S. approval does not remove the limitations of single-arm and external-control studies. EMA · Yartemlea assessment
Financial complexity is another risk. The post-repurchase cash balance, convertible principal, derivative valuation, royalty obligation and unused ATM capacity are separate measures. Mixing them can materially distort the funding picture. The new studies and retained research also require resources, while potential partner milestones remain conditional. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader reading. For existing shareholders, the central test is whether the U.S. commercial franchise can generate durable cash while maintaining safety, funding a focused pipeline and preserving a manageable capital structure. Reported recurring demand and cash conversion would strengthen that reading. Slowing use, adverse safety or access changes, expensive financing or undisciplined spending would weaken it. This is an analysis of evidence and operating risks, not a recommendation or a price forecast. SEC · Q3 Form 10-Q, November 16, 2026
Merlintrader Health Score · OMER
3.10out of 5
Merlintrader editorial assessment · November 18, 2026. All five pillars reassessed; total unchanged. Merlintrader calculation: 3.0×30% + 2.5×30% + 3.5×20% + 3.0×10% + 4.5×10% = 3.10/5. Financial evidence · Commercial and development update · FINRA October 30 settlement. The score describes robustness, not a valuation, target or recommendation.
OMER red flags
- Cash and short-term investments fell from $132.0M at June 30 to $95.3M at September 30 after the July note repurchases.
- The gross-to-net adjustment rose to 14.0% in Q3 from 11.5% as 340B purchases increased.
- NTAP maximum payments depend on case eligibility and the formula.
- The CHMP maintained its refusal recommendation; named-patient efforts are not authorization.
- Net loss includes a $62.0M non-cash derivative loss.
- Repurchases reduce conversion exposure but consume cash; incentive and ATM capacity can still dilute.
- U.S. safety warnings and execution risks remain despite approval.
OMER Stock FAQ: Omeros Corporation Questions Answered
When is the next OMER stock catalyst?
Omeros reported third-quarter 2026 results on November 16, 2026, and held a conference call. Its next company-guided steps are the start of two YARTEMLEA studies, in ARDS and in TA-TMA prevention, expected in late 2026 or early 2027, Medicare outpatient reimbursement for 340B-acquired YARTEMLEA from January 1, 2027, and OMS527 Phase 2 enrollment in the first quarter of 2027. No exact study start date is announced. Medicare NTAP took effect October 1. November 16 results and outlook. Effective reimbursement milestone. Omeros investor news.
Is Omeros’ YARTEMLEA FDA approved?
Yes: YARTEMLEA’s December 2025 U.S. label approves narsoplimab-wuug for hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and children aged two and older. Its European application followed a separate review: the CHMP maintained a refusal recommendation after re-examination in October 2026. Approved U.S. indication. European regulatory outcome.
How much cash does Omeros have, and how long will it last?
Omeros held $95.3 million of cash and short-term investments at September 30, 2026, after the July note repurchases, and generated $13.3 million of operating cash in the third quarter. In its September Form 10-Q, management expects to fund more than twelve months of operations from the issuance of the financial statements, using current resources and expected YARTEMLEA sales receipts. Later sales, spending and financing affect liquidity. Dated liquidity, repurchases and funding assumptions.
Is OMER stock at risk of dilution?
Omeros reported 74,463,571 common shares on November 11, 2026, with equity awards and convertible debt creating potential dilution. July repurchases reduced remaining 2029-note principal to approximately $40.3 million and shares issuable on conversion from about 11.4 million to 6.5 million. No shares were sold under the $150 million ATM in the first nine months of 2026. The transactions reduced potential note-related shares but consumed cash; future funding can still affect ownership. Share count, debt and repurchases.
When does Omeros report earnings?
Omeros reported third-quarter 2026 results after the market close on Monday, November 16, 2026, and held a conference call and webcast the same day. Its latest reported quarter ended September 30, 2026. As of November 16, 2026, the date of the fourth-quarter report has not been announced. November 16 results. Latest quarterly filing. Omeros investor news.
What does Omeros Corporation do?
Omeros develops and commercializes medicines targeting immunologic and other biological pathways. Its U.S. commercial product YARTEMLEA treats eligible hematopoietic stem cell transplant-associated thrombotic microangiopathy patients. The business combines its launch and reimbursement work with additional clinical research and pipeline development. Company and commercial product.
Is Omeros’ YARTEMLEA approved in Europe?
No: the October 2026 re-examination confirmed the CHMP’s refusal recommendation for YARTEMLEA. Omeros said it intended to end EU compassionate use while supplying existing patients’ courses and pursuing reimbursed named-patient access where permitted. Those access arrangements do not constitute EU marketing authorization. Dated company statement. EMA re-examination record.
What is Omeros’ YARTEMLEA Medicare NTAP payment?
Omeros’ YARTEMLEA has a maximum Medicare NTAP add-on of $287,079 for eligible cases under the FY2027 provision effective October 1, 2026. It is not an automatic payment for every case or the medicine’s price. Eligibility and the case-specific reimbursement formula determine the actual payment. CMS FY2027 rule. Published rule and payment provisions. Omeros August 3, 2026 NTAP announcement.
Primary sources
- November 16, 2026 — Third-quarter 2026 results and conference call
- November 16, 2026 — Form 10-Q for the quarter ended September 30, 2026
- November 16, 2026 — Form 8-K, results of operations
- November 10, 2026 — Q3 2026 results date and conference call announced
- October 30 Form 8-K (CEO performance option)
- June Form 10-Q
- Q2 release
- October 16 European update
- EMA product assessment
- CMS FY2027 rule
- Federal Register rule PDF
- U.S. label
- August incentive registration
- July ownership disclosure
- July repurchase filing
- Novo closing announcement
- Khaled et al., J Clin Oncol 2022
- Matsui et al., Blood Advances 2026
- Schoettler et al., Am J Hematol 2025
- Castelli et al., Bone Marrow Transplant 2024
- Omeros · permanent reimbursement J-code announcement
- AstraZeneca · regulatory announcement, July 27, 2026
- October 30 Form 4 · code A; no shares vested at grant
- SEC · Omeros Schedule 13G filings
- FINRA · October 30, 2026 equity short interest
- Federal Register · FY2027 IPPS final rule, August 4, 2026
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $OMER or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Educational and financial disclaimer. This publication is provided exclusively for informational, journalistic and educational purposes. It is not investment advice, financial advice, medical advice, a solicitation, an offer, a recommendation to buy or sell securities, or a personalized trading plan. Nothing above considers the reader’s financial situation, objectives, risk tolerance, tax position or jurisdiction.
Biotechnology securities can be extremely volatile and may react sharply to regulatory decisions, clinical data, reimbursement rules, commercial-launch results, financing transactions, analyst research and market sentiment. Forward-looking scenarios are interpretations based on publicly available information and are not forecasts or guarantees. Readers should perform independent due diligence and consult appropriately qualified financial, legal, tax or medical professionals where relevant. This content is intended for a mixed U.S./European audience and should not be interpreted as regulated investment research under SEC, FINRA or other local rules.
See the Merlintrader Disclaimer and Terms of use and privacy information.



